Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naive older or frail patients with metastatic colorectal cancer (OGSG 0802).
2020
BACKGROUND: Older or frail patients are often underrepresented in clinical trials for metastatic colorectal cancer (mCRC). We here assessed the efficacy and safety of 5-fluorouracil (5-FU)-leucovorin plus bevacizumab in such patients. METHODS: The study (OGSG 0802) was designed as a single-arm, open-label, multicenter phase II trial. Eligible patients had mCRC and at least one of the following: an age of >/= 65 years, an Eastern Cooperative Oncology Group performance status of 1 or 2, a serum albumin level of /= 3 were neutropenia (24%), anorexia (10%), leukopenia (7%), and mucositis/stomatitis (7%). There were no treatment-related deaths. CONCLUSION: Weekly 5-FU-leucovorin with biweekly bevacizumab may be a tolerable and effective treatment option for older or frail patients with mCRC.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
20
References
3
Citations
NaN
KQI